Valuation: Ocugen, Inc.

Market Cap 416M 362M 337M 309M 584M 39.75B 593M 3.97B 1.56B 19.79B 1.56B 1.53B 66.35B P/E 2026 *
-5.51x
P/E 2027 * -5.07x
Enterprise Value 354M 308M 286M 263M 496M 33.78B 504M 3.38B 1.32B 16.82B 1.33B 1.3B 56.39B EV / Sales 2026 *
86.4x
EV / Sales 2027 * 36.7x
Free-Float
98.28%
Yield 2026 *
-
Yield 2027 * -
1 week+1.13%
1 month-20.56%
3 months-26.94%
6 months-11.93%
Current year-15.76%
1 week 1.03
Extreme 1.026
1.13
1 month 1.03
Extreme 1.026
1.36
3 years 0.33
Extreme 0.3264
2.35
5 years 0.33
Extreme 0.3264
15.88
Manager TitleAgeSince
Chief Executive Officer 62 2019-09-26
Director of Finance/CFO - 2026-02-08
Chief Operating Officer - 2026-02-28
Director TitleAgeSince
Chairman 62 2019-09-26
Director/Board Member 59 2013-08-31
Director/Board Member 59 2019-08-31
Change 5-day change 1-year change 3-year change Capi.($)
+1.30%+1.13%+16.99%+97.28% 416M
+1.19%+1.47%+0.35%+15.84% 48.53B
-2.41%-0.90%+411.96%+472.09% 39.87B
-1.16%+12.96%+28.81%+7.27% 38.68B
-1.88%-3.03%+5.69%+66.52% 35.13B
-1.74%+5.12%+14.44%+44.64% 29.79B
-0.21%-4.04%+36.40%+126.06% 16.11B
-2.85%-3.92% - - 16.08B
+0.79%+2.72%+3.31%+16.75% 13.61B
-1.19%-1.32%-1.73%-34.97% 12.62B
Average -0.86%+1.05%+57.36%+90.16% 27.82B
Weighted average by Cap. -0.79%+2.03%+80.09%+108.18%

Financials

2026 *2027 *
Net sales 4.09M 3.56M 3.31M 3.04M 5.74M 391M 5.83M 39.05M 15.33M 195M 15.38M 15.04M 652M 11.35M 9.87M 9.18M 8.43M 15.92M 1.08B 16.17M 108M 42.48M 539M 42.62M 41.69M 1.81B
Net income -76.84M -66.8M -62.18M -57.09M -108M -7.34B -109M -733M -288M -3.65B -289M -282M -12.25B -85.3M -74.15M -69.02M -63.37M -120M -8.14B -122M -814M -319M -4.05B -320M -313M -13.59B
Net Debt -62.5M -54.33M -50.57M -46.43M -87.68M -5.97B -89.04M -596M -234M -2.97B -235M -230M -9.96B -
Logo Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Employees
-
Date Price Change
26-08-03 1.080 +0.56%
26-07-31 €1.074 -1.65%
26-07-30 €1.092 +5.20%
26-07-29 €1.038 -4.42%
26-07-28 €1.086 -2.51%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.230USD
Average target price
12.17USD
Spread / Average Target
+889.16%

Quarterly revenue - Rate of surprise